SGLT 2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Study Objective: Currently only minimal information is available regarding risk factors for the development of sodium glucose cotransporter‐2 inhibitor (SGLT 2i)‐related diabetic ketoacidosis (DKA). We aim to identify individual patient characteristics associated with cases of SGLT 2i‐related DKA to better describe potential risk factors. Design: Systematic review of primary literature. Patients: Thirty‐four case reports of patients with type 1 and type 2 diabetes mellitus who developed DKA while receiving an SGLT 2i. Methods and Main Results: This systematic review investigated the relationship between SGLT 2i and DKA in patients with diabetes. The existing literature was reviewed with a primary outcome to identify patient‐specific factors contributing to the incidence of ketoacidosis in patients with diabetes who were treated with a SGLT 2i. Numerous databases were searched to identify appropriate primary literature. Search terms included canagliflozin, dapagliflozin, empagliflozin, SGLT 2, sodium glucose cotransporter‐2 inhibitor, diabetic ketoacidosis, ketoacidosis, metabolic acidosis, and acidosis. Primary literature was analyzed via descriptive statistics. Thirty‐four individual case reports were identified via the primary literature search. Two‐thirds (25 cases) involved patients with a diagnosis of type 2 diabetes mellitus (T2 DM). The average blood glucose on presentation for SGLT 2i‐induced DKA was 265.6 ± 140.7 mg/dl (14.7 ± 7.8 mmol/L), with common symptoms including nausea, vomiting, and abdominal pain. Common precipitating factors included patients who were diagnosed with T2DM and were subsequently found to have latent autoimmune diabetes of adulthood, patients who had recently undergone major surgery, or patients who had decreased or discontinued insulin. No cases were fatal. Conclusion: In this review, episodes of DKA with SGLT 2i use were characterized by lower blood glucose levels and were often caused by a precipitating factor. Understanding precipitating factors for SGLT 2i‐related DKA may help providers better identify patients at risk for development of DKA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia
Umpierrez, G., & Korytkowski, M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.15 · Cited by 563
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358 · cited 2×
“LADA 9 (36) 0 (0) Surgery 7 (28) 0 (0) Stopped insulin 6 (24) 0 (0) Reduction in insulin 1 (4) 6 (67) Illness 3 (12) 4 (44) Low carbohydrate diet 2 (8) 0 (0) Pancreatitis 2 (8) 0 (0) Dehydration 2 (8) 0 (0) Insulin delivery issue 1 (4) 1 (11) Alcohol 0 (0) 2 (22)”
Hayami, T., Kato, Y., Kamiya, H., Kondo, M., Naito, E., Sugiura, Y., Kojima, C., Sato, S., Yamada, Y., Kasagi, R., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12330 · Cited by 115 · cited 2×
“Vomiting 9 (36) 7 (78) Nausea 4 (16) 5 (56) Abdominal pain 5 (20) 1 (11) Tachycardia 1 (4) 4 (44) Malaise 2 (8) 2 (22) Tachypnea 2 (8) 2 (22) Altered mental status 2 (8) 1 (11) Dizziness 1 (4) 1 (11) Syncope 1 (4) 1 (11) Diarrhea 2 (8) 0 (0)”
Cited by
Hamblin, P. S., Wong, R., Ekinci, E. I., Fourlanos, S., Shah, S., Jones, A. R., Hare, M. J. L., Calder, G. L., Epa, D. S., George, E. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00139 · Cited by 126
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab274 · Cited by 97
Mehta, P. B., Robinson, A., Burkhardt, D., & Rushakoff, R. J. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.06.006 · Cited by 64
Bamgboye, A. O., Oni, I. O., & Collier, A. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03051-3 · Cited by 48
Postoperative outcomes among sodium-glucose cotransporter 2 inhibitor users
Tallarico, R. T., Jing, B., Lu, K., Chawla, S. A., Luo, Y., Badathala, A., Chen, C. L., Wallace, A. W., & Legrand, M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.0940 · Cited by 40
Metadata
- Authors
- Burke, K. R., Schumacher, C. A., & Harpe, S. E.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2017-01-16
- Volume
- 37
- Issue
- 2
- Pages
- 187-194
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2559759755
- Cited by
- 184
- References
- 7
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SGLT 2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. https://app.cochat.ai/papers/10.1002/phar.1881
- The paper
- Burke, K. R., Schumacher, C. A., & Harpe, S. E. (2017). SGLT 2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.1881
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.